Showing results (1-10 of 225) with videos related to
Sort By:
Pageof 23
Expert Review of Clinical Pharmacology|June 4, 2014
Salvage therapy for recurrence of bladder cancer: do we need a uniform approach?Roberto IacovelliExpert Opinion on Emerging Drugs|May 19, 2015
Emerging tyrosine kinase inhibitors for the treatment of renal cancerRoberto Iacovelli, Laurence Albiges, Bernard EscudierTherapeutic Advances in Urology|June 2, 2012
Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desertAmelia Altavilla, Roberto Iacovelli, Giuseppe Procopio, et al.Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 20, 2014
Clinical and pathological features of primary renal angiosarcomaRoberto Iacovelli, Valentina Orlando, Antonella Palazzo, et al.Clinical Genitourinary Cancer|August 25, 2018
De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?Roberto Iacovelli, Chiara Ciccarese, Claudia Mosillo, et al.BJU International|October 31, 2012
Tumour burden is an independent prognostic factor in metastatic renal cell carcinomaRoberto Iacovelli, Emilie Lanoy, Laurence Albiges, et al.Cancer Biology & Therapy|November 21, 2013
First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profileRoberto Iacovelli, Elena Verzoni, Filippo De Braud, et al.Cancer Biology & Therapy|February 22, 2014
Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?Roberto Iacovelli, Elena Verzoni, Filippo Maria De Braud, et al.Anti-Cancer Drugs|November 30, 2011
Abiraterone acetate in castration-resistant prostate cancerRoberto Iacovelli, Antonella Palazzo, Giuseppe Procopio, et al.Therapeutic Advances in Urology|October 2, 2015
Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinomaDaniele Alesini, Claudia Mosillo, Giuseppe Naso, et al.Pageof 23